INC boosts presence in Japan, Asia with new move

After recently merging with fellow CRO InVentiv in a new company worth around $7.4 billion, INC says it is now focused on growing its Asia presence with moves and an expansion.

It says it has outgrown its former digs and has moved into a more spacious Tokyo, Japan office in what it says “supports the company’s long-term growth strategy both in Japan and across the Asia/Pacific region.”

In the last two and a half years, INC says its Tokyo ops “rapidly outgrew” its old offices due to a more than fourfold increase in head count.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Our continued expansion in Tokyo demonstrates our commitment to becoming the global ‘CRO of Choice’ within this vibrant pharmaceutical market for regional and global clinical trials,” said Miranda Porter, Ph.D., SVP of clinical development, Tokyo.

RELATED: INC Research and inVentiv Health merge in another major CRO deal

“Our employees provide global expertise within our therapeutically aligned delivery model while providing local experience and knowledge of Japan’s regulatory, healthcare and cultural environments. Our continued expansion in the country is making a strong contribution to INC’s overall growth.”

INC’s experience from Tokyo focuses on CNS and general medicine and cancer trials.

This comes around two months from its large and unexpected deal to merge with InVentiv. The new company will be headquartered in Raleigh, North Carolina, (where INC is based) and said at the time that it would have a “significant presence in the Northeast corridor of the United States, and operations worldwide, including in Asia and Europe.”

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.